NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors
Pharmacological Research · 2024
DOI: 10.1016/j.phrs.2024.107375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2024. Verfasst von Nutan Sharma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, Mechanistic Target of Rapamycin Complex 1. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Engineering Research Board, Department of Science and Technology, Ministry of Science and Technology, India, Department of Biotechnology.
Abstract (Originalsprache)
The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) is a growing concern for the high incidence rate of hepatocellular carcinoma (HCC) globally. The progression of NAFLD to HCC is heterogeneous and non-linear, involving intermediate stages of non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. There is a high unmet clinical need for appropriate diagnostic, prognostic, and therapeutic options to tackle this emerging epidemic. Unfortunately, at present, there is no validated marker to identify the risk of developing HCC in patients suffering from NAFLD or NASH. Additionally, the current treatment protocols for HCC don't differentiate between viral infection or NAFLD-specific etiology of the HCC and have a limited success rate. The mammalian target of rapamycin complex 1 (mTORc1) is an important protein involved in many vital cellular processes like lipid metabolism, glucose homeostasis, and inflammation. These cellular processes are highly implicated in NAFLD and its progression to severe liver manifestations. Additionally, hyperactivation of mTORc1 is known to promote cell proliferation, which can contribute to the genesis and progression of tumors. Many mTORc1 inhibitors are being evaluated for different types of cancers under various phases of clinical trials. This paper deliberates on the strong pathological implication of the mTORc1 signaling pathway in NAFLD and its progression to NASH and HCC and advocates for a systematic investigation of known mTORc1 inhibitors in suitable pre-clinical models of HCC having NAFLD/NASH-specific etiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India; Department of Chemistry, Faculty of Applied and Basic Sciences,…
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India.
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India. Electronic address: dinesh.mahajan@thsti.res.in.
Förderung
- Science and Engineering Research Board
- Department of Science and Technology, Ministry of Science and Technology, India
- Department of Biotechnology
- Biotechnology Industry Research Assistance Council
Zitieren
APA
Sharma, N., Singh, L., Sharma, A., Kumar, A., & Mahajan, D. (2024). NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107375
Vancouver
Sharma N, Singh L, Sharma A, Kumar A, Mahajan D. NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107375
BibTeX
@article{Sharma2024,
author = {Sharma, Nutan and Singh, Lakhwinder and Sharma, Aditya and Kumar, Ajay and Mahajan, Dinesh},
title = {NAFLD-associated hepatocellular carcinoma (HCC) – A compelling case for repositioning of existing mTORc1 inhibitors},
journal = {Pharmacological Research},
year = {2024},
doi = {10.1016/j.phrs.2024.107375}
}
EUVIMED